CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.
Saved in:
| Title: | CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study. |
|---|---|
| Authors: | Pariser, David M.1 (AUTHOR), Lebwohl, Mark G.2 (AUTHOR), Jaworski, Janusz3 (AUTHOR), Trefler, Jakub4 (AUTHOR), Daniluk, Stefan5 (AUTHOR), Dudek, Anna6 (AUTHOR), Baran, Wojciech7 (AUTHOR), Owczarek, Witold8,9 (AUTHOR), Brzewski, Pawel10,11 (AUTHOR), Sikora, Mariusz12 (AUTHOR), Krogulec, Marek13 (AUTHOR), Kim, SungHyun14 (AUTHOR), Suh, JeeHye14 (AUTHOR), Choi, EunJin14 (AUTHOR), Cha, JungBin14 (AUTHOR), Lee, HyunJin14 (AUTHOR), Lee, SungJeong14 (AUTHOR), Koo, John Y.15 (AUTHOR) john.Koo2@ucsf.edu |
| Source: | Dermatology & Therapy. May2025, Vol. 15 Issue 5, p1079-1092. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
